PMID- 10720127
OWN - NLM
STAT- MEDLINE
DCOM- 20000407
LR  - 20190915
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 14
IP  - 3
DP  - 2000 Mar
TI  - Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid 
      leukemia at diagnosis, relapse and during follow-up: a study of 23 patients.
PG  - 364-8
AB  - The value of dual-color fluorescence in situ hybridization (FISH) for the 
      detection of inv(16), using two contigs of cosmid probes mapping on both sides of 
      the chromosome 16p breakpoint region, was evaluated in 23 acute myeloid leukemias 
      (AML) in different phases of the disease. At diagnosis interphase FISH detected 
      inv(16) in 19/19 (100%) cases with conventional cytogenetics (CC) evident 
      aberration and excluded the rearrangement in two patients with CC suspected 
      inv(16). Moreover, it also identified an associated del(16p) in two patients. At 
      relapse, it revealed the inv(16) in 8/8 (100%) studied cases. These results were 
      concordant with those of reverse transcriptase-polymerase chain reaction 
      (RT-PCR). From 13 patients who obtained at least one complete remission (CR), 31 
      follow-up samples were analyzed using interphase FISH. Twenty-nine specimens 
      scored negative for inv(16) and two were positive. RT-PCR detected CBFbeta/MYH11 
      transcripts in four of the nine CR samples analyzed, being more sensitive than 
      interphase FISH. Eight of the 13 patients relapsed at a median time of 6.5 months 
      (range 1-15) from the last negative FISH analysis. Of the two patients with 
      positive FISH in CR, one relapsed soon after. At diagnosis and relapse, 
      interphase-FISH proved to be an effective technique for detecting inv(16) 
      appearing more sensitive than CC. Prospective studies with more frequent controls 
      and possibly additional FISH probes are needed to assess the value of interphase 
      FISH for minimal residual disease (MRD) and relapse prediction.
FAU - Mancini, M
AU  - Mancini M
AD  - Department of Cellular Biotechnology and Hematology, University La Sapienza, 
      Rome, Italy.
FAU - Cedrone, M
AU  - Cedrone M
FAU - Diverio, D
AU  - Diverio D
FAU - Emanuel, B
AU  - Emanuel B
FAU - Stul, M
AU  - Stul M
FAU - Vranckx, H
AU  - Vranckx H
FAU - Brama, M
AU  - Brama M
FAU - De Cuia, M R
AU  - De Cuia MR
FAU - Nanni, M
AU  - Nanni M
FAU - Fazi, F
AU  - Fazi F
FAU - Mecucci, C
AU  - Mecucci C
FAU - Alimena, G
AU  - Alimena G
FAU - Hagemeijer, A
AU  - Hagemeijer A
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - *Chromosome Inversion
MH  - Chromosomes, Human, Pair 16/genetics/*ultrastructure
MH  - Cosmids/genetics
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence/*methods
MH  - *Interphase
MH  - Karyotyping
MH  - Leukemia, Myeloid/epidemiology/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2000/03/17 00:00
MHDA- 2000/03/17 00:01
CRDT- 2000/03/17 00:00
PHST- 2000/03/17 00:00 [pubmed]
PHST- 2000/03/17 00:01 [medline]
PHST- 2000/03/17 00:00 [entrez]
AID - 10.1038/sj.leu.2401678 [doi]
PST - ppublish
SO  - Leukemia. 2000 Mar;14(3):364-8. doi: 10.1038/sj.leu.2401678.